IHMT-15137 是一种 IC50 为 26.97 nM 的 BMX 抑制剂,可与 ATP 结合口袋内的 BMX Cys496 共价结合,抑制 BMX 在 Tyr566 位点的磷酸化,破坏 BMX-ERK1/2-Cyclin D1/CDK4/6-E2F1 信号轴,并通过降低 Ser332/337 位点的磷酸化水平、增加泛素化以及经泛素-蛋白酶体途径降解来降低 E2F1 蛋白的稳定性,从而诱导细胞周期阻滞、细胞凋亡 (apoptosis) 和 DNA 损伤,抑制细胞迁移与侵袭,可用于小细胞肺癌的研究。
IHMT-15137
产品编号: MS-B38812 分子式: C21H21F3N6O2 分子量: 446.43
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

IHMT-15137 是一种 IC50 为 26.97 nM 的 BMX 抑制剂,可与 ATP 结合口袋内的 BMX Cys496 共价结合,抑制 BMX 在 Tyr566 位点的磷酸化,破坏 BMX-ERK1/2-Cyclin D1/CDK4/6-E2F1 信号轴,并通过降低 Ser332/337 位点的磷酸化水平、增加泛素化以及经泛素-蛋白酶体途径降解来降低 E2F1 蛋白的稳定性,从而诱导细胞周期阻滞、细胞凋亡 (apoptosis) 和 DNA 损伤,抑制细胞迁移与侵袭,可用于小细胞肺癌的研究。

生物实验数据

生物活性 IHMT-15137 is a BMX inhibitor with an IC50 of 26.97 nM that covalently binds to BMX Cys496 within the ATP-binding pocket, inhibits BMX phosphorylation at Tyr566, disrupts the BMX-ERK1/2-Cyclin D1/CDK4/6-E2F1 signaling axis, and reduces E2F1 protein stability by decreasing phosphorylation at Ser332/337, increasing ubiquitination, and promoting degradation via the ubiquitin-proteasome pathway, thereby inducing cell cycle arrest, apoptosis, and DNA damage, inhibiting cell migration and invasion, and serving as a potential agent for the study of small cell lung cancer.
体外研究
(In Vitro)

IHMT-15137 (3 μM;24-168 小时) 与 Cisplatin (MS-E94993) (5-30 μM) 协同作用,可降低小细胞肺癌 (SCLC) 患者来源细胞 C23084 和 LUC22009 的活力,诱导 S 期细胞周期阻滞,抑制增殖,促进凋亡,增加 DNA 损伤,并破坏 BMX-ERK1/2-Cyclin D1-E2F1 信号轴。
IHMT-15137 可增强 Cisplatin+Etoposide (MS-Z04043) 在 SCLC 患者来源细胞 C23084 和 LUC22009 中的细胞毒性与抗增殖作用。

Cell Cycle Analysis

Cell Line: SCLC patient-derived cells C23084 and LUC22009
Concentration: 3 μM; 3 μM plus 5 μM Cisplatin
Incubation Time: 48 h
Result: Induced S-phase cell cycle arrest.

Cell Proliferation Assay

Cell Line: SCLC patient-derived cells C23084 and LUC22009
Concentration: 3 μM; 3 μM plus 5 μM Cisplatin
Incubation Time: 14 days
Result: Suppressed cell proliferation compared with DMSO group.

Western Blot Analysis

Cell Line: SCLC patient-derived cells C23084 and LUC22009
Concentration: 10 μM; 10 μM plus 30 μM Cisplatin
Incubation Time: 24 h
Result: Enhanced apoptosis (cleaved PARP and cleaved caspase-3) and significantly increased DNA damage (γ-H2AX) in the treated groups compared with the monotherapies.

Western Blot Analysis

Cell Line: SCLC patient-derived cells C23084 and LUC22009
Concentration: 3 μM; 3 μM plus 30 μM Cisplatin
Incubation Time: 24 h
Result: Potentiated the effects of Cisplatin by modulating the ERK1/2-Cyclin D1/CDK4/6 signaling axis and promoting the degradation of E2F1.
体内研究
(In Vivo)

IHMT-15137 (100 mg/kg;腹腔注射) 联合 Cisplatin 和 Etoposide 可在 H69AR 小细胞肺癌 (SCLC) 异种移植模型中诱导 60.1% 的肿瘤生长抑制,增强细胞凋亡并抑制细胞增殖,且无显著毒性。
IHMT-15137 (100 mg/kg;腹腔注射) 联合 Cisplatin 与 Etoposide 可在 H446DDPR 小细胞肺癌异种移植物中诱导 69.0%的肿瘤生长抑制,增强细胞凋亡并抑制细胞增殖,且无显著毒性。
IHMT-15137 (100 mg/kg;腹腔注射) 联合 Cisplatin 与 Etoposide 可在 SCLC 患者来源异种移植物中诱导 59.8%的肿瘤生长抑制,增强细胞凋亡并抑制细胞增殖,且无显著毒性。

Animal Model: NCG mice (female, 6 weeks old, subcutaneous xenograft model implanted with chemoresistant H69AR cells)
Dosage: 100 mg/kg; 100 mg/kg plus 2 mg/kg Cisplatin plus 16 mg/kg Etoposide
Administration: i.p.
Result: Achieved 60.1% tumor growth inhibition (TGI).
Reduced final mean tumor weight to 0.96 g compared to vehicle control (2.46 g).
Suppressed chemotherapy-induced increases in tumor tissue levels of p-BMX (Tyr566), p-ERK1/2 (Thr202/Tyr204), Cyclin D1, p-E2F1 (Ser332), and p-E2F1 (Ser337).
Increased tumor apoptosis (TUNEL-positive cells) compared to monotherapies.
Reduced tumor proliferation (Ki-67-positive cells) compared to monotherapies.
Caused no significant body weight loss.
Animal Model: NCG mice (female, 6 weeks old, subcutaneous xenograft model implanted with chemoresistant H446DDPR cells)
Dosage: 100 mg/kg; 100 mg/kg plus 2 mg/kg Cisplatin plus 16 mg/kg Etoposide
Administration: i.p.
Result: Achieved 69.0% tumor growth inhibition (TGI).
Reduced final mean tumor weight to 0.78 g compared to vehicle control (2.52 g).
Suppressed chemotherapy-induced increases in tumor tissue levels of p-BMX (Tyr566), p-ERK1/2 (Thr202/Tyr204), Cyclin D1, p-E2F1 (Ser332), and p-E2F1 (Ser337).
Increased tumor apoptosis (TUNEL-positive cells) compared to monotherapies.
Reduced tumor proliferation (Ki-67-positive cells) compared to monotherapies.
Caused no significant body weight loss.
Animal Model: NCG mice (female, 6 weeks old, subcutaneous patient-derived xenograft model implanted with PDC C23084 cells)
Dosage: 100 mg/kg; 100 mg/kg plus 2 mg/kg Cisplatin plus 16 mg/kg Etoposide
Administration: i.p.
Result: Achieved 59.8% tumor growth inhibition (TGI).
Reduced final mean tumor weight to 0.39 g compared to vehicle control (0.97 g).
Suppressed chemotherapy-induced increases in tumor tissue levels of p-BMX (Tyr566), p-ERK1/2 (Thr202/Tyr204), Cyclin D1, p-E2F1 (Ser332), and p-E2F1 (Ser337).
Increased levels of cleaved PARP and cleaved caspase-3 (apoptosis markers).
Increased tumor apoptosis (TUNEL-positive cells) compared to monotherapies.
Reduced tumor proliferation (Ki-67-positive cells) compared to monotherapies.
Caused no significant body weight loss.

化学信息

分子量 446.43
分子式 C21H21F3N6O2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础